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720a Wednesday, February 19, 2014either detectable changes in [Ca2þ]i or in barrier function which pointed to
a complex role of Ca2þ signaling, if any, in endothelial barrier regulation.
Absent or inconsistent [Ca2þ]i transients under conditions of increased cellular
confluency further challenge a role of Ca2þ-mediated signaling in receptor-
mediated disruption of barrier integrity. A thorough pharmacological examina-
tion revealed that different SOC inhibitors (e.g. lanthanides, 2-APB, BTP2)
completely abrogated store-operated calcium entry (SOCE) while having no
effect on receptor-mediated disruption of endothelial barrier function thus
suugesting that SOCE is not required for endothelial barrier regulation.
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The combination of human induced pluripotent stem cell-differentiated cardi-
omyocytes (hiPSC-CMs) with multi-electrode array (MEA) technology allows
for a medium throughput assessment of cardiovascular risk at preclinical stages
of drug discovery well in advance of candidate selection. Field potential dura-
tion (FPD) is a surrogate marker for QT duration and, like QT duration, is beat
rate-dependent. Correction for changes in rate is required to properly interpret
direct effects on FPD or QT. The FPD is defined as the time interval between
initiation of the fast (Naþ spike) voltage deflection due to INa and subsidence of
the slow, positive deflection due to repolarizing IK currents, and is a biomarker
for QT duration. Our data demonstrate that FPD is highly correlated with
the beat period in a largely non-linear fashion. Additionally, non-paced
hiPSC-CMs are susceptible to dramatic drug-induced beat period changes.
Consequently, interpretation of the effects of drugs on these parameters
requires a beating rate correction. However, commonly used human ECG-
derived QT correction formulae (e.g. Fredericia’s, Bazett’s) prove inadequate
outside a narrow range of FPD-beat period linearity. Their use may incorrectly
classify QT/FPD modifying compounds. We therefore developed and qualified
a set of algorithms for FPD:beat period correction based on the response of
hiPSC-CMs to the If inhibitor ZD7288 and the beta adrenergic agonist isopro-
terenol. The resulting FPD:beat period relationship had a limited linear range
and an extended non-linear range. These algorithms were compared to other
common correction methods. We found that individual correction provided a
statistically significantly improvement over classical correction formulae
(on parameters of linearity & slope) in the non-linear range. This correction
algorithm has been incorporated into our MEA assay for QT risk assessment.
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Blockade of the human ether-a-go-go-related gene (hERG) ion channel is a
marker for pro-arrhythmic risk. However, the extent of hERG channel inhibi-
tion is poorly correlated with action potential duration (APD) prolongation in
vitro, due to multi-channel block. Subsequently, compounds which block mul-
tiple ion channels may be overlooked by pre-clinical safety screening when
measuring voltage alone, with the potential risk of late stage drug attrition
and withdrawal. In this work we propose optical measurements of voltage
and intracellular calcium ([Ca2þ]i) in hiPSC-CMs as an alternative to the cur-
rent drug screening methods to distinguish mixed action drugs in early stages.
We used hiPSC-CMs loaded with 3mM di-4-ANEPPS to record membrane po-
tential and 1mM Fura 4-AM to measure [Ca2þ]i from areas of iPSCs using Cel-
lOPTIQ platform (Clyde Biosciences, Glasgow UK). Fluorescence signals
were digitized at 10kHz and analyzed off-line using proprietary software.
Mixed ion channel blockade was mimicked by the co-administration of E-
4031 (hERG blocker) and Nifedipine (Ca2þ channel blocker). The results
showed that at a critical combined concentrations (e.g. 30nM E4031 þ
30nM Nifedipine) which individually prolonged and shortened APD at 75%
of repolarisation (APD75) respectively, in combination did not significantly
change APD75 from baseline (APD75 6.5 5 7% of control), whereas[Ca2þ]i was markedly reduced (by 18 5 1.2% change, p<0.05). Low con-
centrations of Verapamil (30nM), an antiarrhythmic drug with known mixed
hERG and L-type Ca2þ channel activity, had no significant effect on APD
(APD75 1.5 5 0.7%) whereas the amplitude of Ca2þ transient was signifi-
cantly reduced (by 455 8%, p<0.05). In conclusion, simultaneous measure-
ments of [Ca2þ]i and voltage provides a convenient indicator of mixed ion
channel effects when screening for drug-induced cardiotoxicity.
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Heart-related health problems remain a leading cause of mortality in developed
countries. To efficiently fight these problems, cardiology needs an information-
rich screening for new drug candidates. Recent achievements in stem cell
research provide a long-awaited solution by producing human stem-cell
derived cardiomyocytes and, thus, providing various "disease-in-a-dish"
models of cardiac disorders.
Two biologically distinct parameters are required to efficiently characterize the
cardiomyocytes function: changes in cell membrane potential and distribution
of intracellular calcium ions. Unfortunately, due to experimental limitations
and lack of appropriate fluorescent indicators, the traditional approach to
perform such an assessment is to record one signal at a time.
Here we present novel approach to perform multi-parametric assessment of
cardiomyocytes while using two functionally different fluorescent indicators
excited by the same wavelength of light. Specifically, using the IC200 HCS
screening system (Vala Sciences), we performed a functional assessment of
stem cell-derived cardiomyocytes by parallel optical recording of two physio-
logically distinct signals in real time: dynamic changes in cell membrane
voltage as well as redistribution of calcium ions in cells. To do that, in addition
to a calcium indicator Fluo4, we used a novel highly efficient voltage-sensitive
fluorescent dye (VF 2.1) to detect voltage changes in cardiomyocytes.
To perform data analysis, we have developed a dedicated software program that
by creating spatially distinct subsets of masks is separating calcium and voltage
signals. Using our multiparametric assay, we have performed several screening
campaigns using benchmark compounds such as modulators of ion channels
involved in generation of cardiac action potential (hERG channels, sodium
and calcium voltage-gated ion channels), as well as drugs that affect the intra-
cellular calcium handling. In summary, we have developed a multi-parametric
approach for comprehensive screening of a human stem cell-derived cardio-
myocytes for drug discovery and cardiotoxicity purposes.
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Drug-induced cardiac arrhythmias characterized by QT prolongation have been
a major reason for drug withdrawal at late stage of clinical trials. Species dif-
ference is a cause of insufficient predictability of current drug safety models.
Therefore, human induced pluripotent stem cell-derived cardiomyocytes
(hiPS-CMs) have great promise for application of cardiac drug safety testing
as a human cardiac model. Our perforated patch-clamp recordings from
hiPS-CMs revealed that the cells exhibited diverse shapes of spontaneous
action potentials (APs) with relatively small upstroke velocity (~10V/s) and
depolarized maximum diastolic potential (MDP; >-50 mV), which represents
rather immature forms of cardiac cells. Actually, a selective hERG blocker,
E4031,depolarized significantly MDP and stopped spontaneous beatings on a
monolayer of hiPS-CMs, which makes it difficult to evaluate the effects on
AP durations.Thus, in order to improve evaluation of risks for drug-induced
QT prolongation in hiPS-CMs, we generated ventricular-like hiPS-CMs by
over-expressing protein-X into hiPS-CMs and characterized the utility for eval-
uation of drug effects on cardiac repolarization process. The protein-X over-
expression made hiPS-CMs quiescent with hyperpolarized MDP (67 mV),
and were excitable with rapid upstroke velocity (~95 V/s) by electrical field
stimulation. When E4031 was applied to hiPS-CMs overexpressing protein-
X, both AP durations of single myocytes and extracellular field potential
durations of cardiac sheets were prolonged in a dose dependent manner. These
results suggest that hiPS-CMs engineered with gene X would be a novel
